NCT07443514Recruiting
Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
This prospective, non-randomized diagnostic interventional study evaluates cognitive impairment in patients with diffuse large B-cell lymphoma (DLBCL) treated at the Institute of Oncology Ljubljana. Chemotherapy regimens are administered according to clinical indication and are not assigned by the study protocol. The research intervention consists of structured neurocognitive assessments and biomarker analyses performed at predefined time points during treatment and follow-up. Cognitive function will be assessed at baseline, after the first chemotherapy cycle, and 12 months after treatment initiation. In patients receiving intrathecal chemotherapy, cerebrospinal fluid (CSF) biomarkers will be analyzed using samples collected during clinically indicated lumbar punctures. The study aims to characterize the frequency, severity, and trajectory of cognitive impairment and to identify clinical and biological predictors of treatment-associated cognitive changes in patients with DLBCL.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- First submitted
- 11 Feb 2026
- Start date
- 1 Jan 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Institute of Oncology Ljubljana
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07443514
What you commit to
- Study type: Interventional
- Planned participants: 3
- From 1 Jan 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe cognitive impairment preventing completion of neurocognitive testing
- Severe psychiatric disorder or neurological disease interfering with cognitive assessment
Other
- Inability to understand study procedures or complete questionnaires
- Refusal or inability to provide informed consent
Who the study is looking for
- Adults aged 18 to 80 years
- Newly diagnosed diffuse large B-cell lymphoma (DLBCL) planned for treatment with systemic chemotherapy (R-CHOP) with or without intrathecal chemotherapy
- Ability to provide written informed consent
- For healthy volunteer/control group: relatives of participating patients willing to undergo cognitive testing and questionnaires
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.